Navigation Links
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Date:10/22/2008

Arginine vasopressin (AVP) receptor antagonist now approved in single-use

premixed formulation

DEERFIELD, Ill., Oct. 22 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new premixed formulation of Vaprisol: Vaprisol(R) (conivaptan hydrochloride injection) Premixed in 5% Dextrose. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients. Hyponatremia is a potentially life-threatening condition that occurs when the body's blood sodium level falls significantly below normal. Vaprisol was originally approved by the FDA in an ampule formulation for the treatment of euvolemic hyponatremia in December 2005 and hypervolemic hyponatremia in February 2007.

The 100mL, single-use premixed formulation of Vaprisol comes in an INTRAVIA(R) Container, a product of Baxter Healthcare Corporation, containing 20 mg of conivaptan hydrochloride in 5% Dextrose solution. Lactic acid, USP is added for pH adjustment to pH 3.4 to 3.8. The new formulation will make preparation easier for health care providers as it is requires no measuring or mixing. Additionally, it has an expiration date of 24 months, six months longer than the original ampule formulation.

"Vaprisol Premixed in 5% Dextrose will be helpful in quickly preparing treatment for hyponatremia patients," said Dr. Joseph Verbalis, M.D., Professor of Medicine and Physiology at Georgetown University. "This ready-to- use product will be useful for hospitals and emergency rooms."

Hyponatremia is present in approximately 28 percent of patients upon admission into acute hospital care and another 14 percent acquire the condition while in acute care. Severe cases are medical emergencies that can result in swelling of the brain, respira
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
2. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
3. FDA Approves Fougeras Clotrimazole Cream USP 1%
4. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
5. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
6. Signalife Board Approves Merger
7. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
8. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
9. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
10. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
11. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... Students and faculty from Beijing City University ... “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. ... from both universities and is taught on both continents. , “Our alliance with ...
(Date:6/30/2015)... June 30, 2015  Today, Americord Registry, one of the ... Andrew Horne , a partner at Kirkland & Ellis LLP, ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are ... Board," says Martin Smithmyer , CEO of Americord. "He ... career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... June 30, 2015 , ... Matrix Marketing Group, LLC , ... hired Gem Swartz to head up its account management department as vice president of ... and Amanda bring senior account management and delivery expertise to the growing Matrix Marketing ...
(Date:6/30/2015)... IL (PRWEB) , ... June 30, 2015 , ... ... effective August 14. She has accepted the position of vice president of instruction ... August 17. , “I greatly appreciated the opportunity to lead SIUE during ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2Matrix Marketing Group Expands Client Services Team 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... Heritage has recently,overcome patent claims held by a competitor ... and databases that allow families around,the world to match ... the,use of surnames and Y-chromosomes to establish a family ... rendered a formal opinion,stating that the relevant claims are ...
... of advanced neuromodulation products designed to accelerate recovery from central ... largest provider of inpatient rehabilitative healthcare services, will expand the ... NESS L300™ Foot Drop System to 88 rehabilitation hospitals nationwide. ... ...
... OSAKA, Japan, July 30 /PRNewswire/ - Cytochroma and,Mitsubishi ... have signed a license agreement under which Cytochroma ... Asia, including Japan, to develop,and commercialize CTA018, Cytochroma,s ... development in Canada for the treatment of secondary,hyperparathyroidism ...
Cached Biology Technology:DNA Heritage Success in Patent Battle Helps Keep Genealogy DNA Test Prices Low 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia 2Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia 3Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia 4
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... that are linked with the onset of Barrett,s oesophagus (BE), ... have been identified for the first time. The discovery of ... develop screening tests for people at high risk of developing ... that there may be genetic causes for BE as well ...
... Sunday, September 9, 2012 A new paper published online ... the second most common type of lung cancer may one ... other lung cancer patients. Squamous cell lung cancer ... cancer, ranking second only to lung adenocarcinoma in the number ...
... 7, 2012 The University of Illinois at ... teams joining the NASA Astrobiology Institute (NAI) to study the ... approximately $8 million. Nigel Goldenfeld, Swanlund Professor of ... Institute for Genomic Biology (IGB), will serve as the principal ...
Cached Biology News:Researchers find first evidence for a genetic cause for Barrett's oesophagus 2Researchers find first evidence for a genetic cause for Barrett's oesophagus 3New potential targets discovered for treating squamous cell lung cancers 2New potential targets discovered for treating squamous cell lung cancers 3University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 2University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 3
... The CopyControl™ vector can be induced prior ... vectors provide the stability of single-copy BACs ... or other cloning vectors. The kits provide ... reagents, insert size screening system) necessary to ...
... EPICENTREs patented MasterAmp™ 10X PCR ... performance and allows improved sensitivity and ... templates. Using MasterAmp™ PCR Enhancer in ... of DNA melting, increases enzyme?s thermal ...
... Streptavidin-AP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
Biology Products: